News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,475 Results
Type
Article (14107)
Company Profile (295)
Press Release (253073)
Section
Business (81123)
Career Advice (149)
Deals (13695)
Drug Delivery (32)
Drug Development (50631)
Employer Resources (31)
FDA (5816)
Job Trends (5164)
News (147050)
Policy (10303)
Tag
Academia (909)
Alliances (22363)
Alzheimer's disease (735)
Approvals (5787)
Artificial intelligence (61)
Bankruptcy (97)
Best Places to Work (4527)
Biotechnology (242)
Breast cancer (64)
Cancer (674)
Cardiovascular disease (58)
Career advice (130)
CAR-T (54)
Cell therapy (174)
Clinical research (40057)
Collaboration (233)
Compensation (96)
COVID-19 (1007)
C-suite (64)
Cystic fibrosis (63)
Data (760)
Diabetes (73)
Diagnostics (1283)
Earnings (29366)
Events (47340)
Executive appointments (180)
FDA (6101)
Funding (236)
Gene editing (55)
Gene therapy (144)
GLP-1 (300)
Government (1071)
Healthcare (6654)
Infectious disease (1040)
Inflammatory bowel disease (92)
IPO (7245)
Job creations (881)
Job search strategy (126)
Layoffs (184)
Legal (1483)
Lung cancer (109)
Manufacturing (78)
Medical device (2703)
Medtech (2704)
Mergers & acquisitions (6542)
Metabolic disorders (221)
Neuroscience (930)
NextGen Class of 2024 (2025)
Non-profit (843)
Northern California (924)
Obesity (123)
Opinion (91)
Parkinson's disease (57)
Patents (48)
People (25318)
Pharmaceutical (49)
Phase I (14063)
Phase II (18623)
Phase III (11811)
Pipeline (317)
Postmarket research (867)
Preclinical (5939)
Radiopharmaceuticals (204)
Rare diseases (159)
Real estate (1500)
Regulatory (8368)
Research institute (942)
Southern California (849)
Startups (1995)
United States (7479)
Vaccines (160)
Weight loss (76)
Date
Today (117)
Last 7 days (596)
Last 30 days (2185)
Last 365 days (20829)
2024 (18923)
2023 (22679)
2022 (27896)
2021 (28772)
2020 (24039)
2019 (16582)
2018 (11992)
2017 (14104)
2016 (12131)
2015 (14801)
2014 (10725)
2013 (7753)
2012 (7878)
2011 (7943)
2010 (7696)
Location
Africa (147)
Asia (17101)
Australia (2901)
California (2093)
Canada (712)
China (157)
Colorado (79)
Connecticut (83)
Europe (39187)
Florida (218)
Georgia (60)
Illinois (128)
Indiana (54)
Kansas (55)
Maryland (297)
Massachusetts (1676)
Michigan (50)
Minnesota (93)
New Jersey (531)
New York (601)
North Carolina (398)
Northern California (924)
Ohio (78)
Pennsylvania (435)
South America (214)
Southern California (849)
Texas (219)
Washington State (214)
267,475 Results for "acousia therapeutics gmbh".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease
Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors.
January 9, 2024
·
2 min read
Drug Development
Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Acousia Therapeutics received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ACOU085 in patients with cisplatin-induced hearing loss.
October 9, 2023
·
2 min read
Drug Development
Hearing loss company Acousia Therapeutics completes clinical Phase 1 study with its small molecule
Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last patient treated with the highest ACOU085 dose.
December 12, 2022
·
1 min read
Deals
Great Point Partners Acquires Lyocontract GmbH, Germany-Based Drug Product CDMO
Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, announced the acquisition of Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization based in Ilsenburg, Germany.
June 13, 2024
·
3 min read
Business
Oakwood Chemical Announces Strategic Partnership with EMP Biotech GmbH
Oakwood Chemical is thrilled to unveil its collaboration with EMP Biotech GmbH, a move set to streamline the oligo synthesis supply chain.
April 9, 2024
·
2 min read
Press Releases
FGK Clinical Research GmbH Highlights 3.5 Years of Success with Flex Databases
October 10, 2024
·
1 min read
Drug Development
HD Immune GmbH Foundation and Publication of Latest Pre-Clinical Data
HD Immune GmbH announces commencement of operations by its two founders Dr. Stefan Bartl and Dr. Lionel Wightman.
January 23, 2024
·
2 min read
Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that...
April 17, 2024
·
3 min read
Press Releases
Dovetail Genomics and Goenomics GmbH Announce Strategic Partnership to Enhance Genome Annotation Services
August 21, 2024
·
4 min read
Biocure Technology Inc. Enters into Exclusive Letter Agreement to Acquire Atriva Therapeutics GmbH in Reverse Takeover Transaction
Biocure Technology Inc. (CSE: CURE) (“CURE” or the “Company”) announces that it has entered into an exclusive letter agreement dated September 8, 2023 with Atriva Therapeutics GmbH.
September 19, 2023
·
8 min read
1 of 26,748
Next
